Fertility and Sterility
Volume 91, Issue 4, Supplement , Pages 1378-1380 , April 2009

GnRH agonist versus GnRH antagonist in controlled ovarian hyperstimulation: their role in patients with an unfavorable prognosis a priori

  • Raoul Orvieto, M.D., M.M.Sc.

      Affiliations

    • Department of Obstetrics and Gynecology, Barzilai Medical Center, Ashkelon, Israel
    • BenGurion University School of Medicine, Beer Sheva, Israel
    • Corresponding Author InformationReprint requests: Professor Raoul Orvieto M.D., M.M.Sc., Director, Infertility and IVF Unit, Department of Obstetrics and Gynecology, Barzilai Medical Center, Ashkelon 78278, Israel (FAX: 972-8-6745134).
    • ,
  • Roy Homburg, F.R.C.O.G.

      Affiliations

    • Department of Obstetrics and Gynecology, Barzilai Medical Center, Ashkelon, Israel
    • ,
  • Simion Meltcer, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Barzilai Medical Center, Ashkelon, Israel
    • ,
  • Jacob Rabinson, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Barzilai Medical Center, Ashkelon, Israel
    • ,
  • Eyal Y. Anteby, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Barzilai Medical Center, Ashkelon, Israel
    • BenGurion University School of Medicine, Beer Sheva, Israel
    • ,
  • Shimon Scharf, M.D., M.P.H.

      Affiliations

    • Department of Obstetrics and Gynecology, Barzilai Medical Center, Ashkelon, Israel
    • BenGurion University School of Medicine, Beer Sheva, Israel

Received 8 February 2008 ,Revised 12 April 2008 ,Accepted 12 April 2008.

References 

  1. Penzias AS. Improving results with assisted reproductive technologies: individualized patient-tailored strategies for ovulation induction. Reprod Biomed Online. 2004;9:43–46
  2. Al-Inany H, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane review. Reprod Biomed Online. 2007;14:640–649
  3. Ludwig M, Katalinic A, Diedrich K. Use of GnRH antagonists in ovarian stimulation for assisted reproductive technologies compared to the long protocol. Meta-analysis. Arch Gynecol Obstet. 2001;265:175–182
  4. Fauser BC, Devroey P. Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow?. Fertil Steril. 2005;83:1607–1611
  5. Griesinger G, Felberbaum R, Diedrich K. GnRH antagonists in ovarian stimulation: a treatment regimen of clinicians' second choice? Data from the German National IVF Registry. Hum Reprod. 2005;20:2373–2375
  6. Orvieto R, Rabinson J, Meltzer S, Homburg R, Anteby E, Zohav E. GnRH agonist versus GnRH antagonist in ovarian stimulation: Is the emperor naked?. Clin Exp Obstet Gynecol. 2006;33:197–199
  7. Orvieto R, Meltcer S, Rabinson J, Zohav E, Anteby EY, Nahum R. GnRH agonist versus GnRH antagonist in ovarian stimulation: the role of endometrial receptivity. Fertil Steril. In press.
  8. Rabinson J, Meltcer S, Zohav E, Gemer O, Anteby EY, Orvieto R. GnRH agonist versus GnRH antagonist in ovarian stimulation: the influence of body mass index on in-vitro fertilization outcome. Fertil Steril. 2008;89:472–474
  9. Orvieto R, Rabinson J, Meltcer S, Gemer O, Anteby EY, Zohav E. Does physicians' experience influence IVF success in patients undergoing controlled ovarian stimulation with GnRH-antagonists?. Fertil Steril. 2008;89:736–737

 R.O. has nothing to disclose. R.H. has nothing to disclose. S.M. has nothing to disclose. J.R. has nothing to disclose. E.A. has nothing to disclose. S.S. has nothing to disclose.

PII: S0015-0282(08)00898-4

doi: 10.1016/j.fertnstert.2008.04.028

Fertility and Sterility
Volume 91, Issue 4, Supplement , Pages 1378-1380 , April 2009

Article Tools